Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening.
Three patients with primary central nervous system (CNS) lymphoma have had major tumor regression with multiagent chemotherapy given in association with reversible blood-brain barrier opening used to enhance drug delivery to the tumor. In addition, in one patient barrier modification was carried out in the posterior fossa by mannitol infusion into the vertebral artery without untoward effects, an approach not heretofore accomplished. Computed tomographic (CT) studies documented that discontinuation of steroids rapidly effected an increase in the delivery of contrast agent to the tumor. CT monitoring of the degree of barrier modification showed tumor nodules and tumor size not apparent on the control scans, thereby providing additional evidence of the existence of a blood-brain barrier in CNS tumors. These studies further show that drug (contrast) delivery to the tumor, as well as to the surrounding barrier, is enhanced after reversible blood-brain barrier modification. Finally, chemotherapy administered by this approach resulted in defined, objective tumor responses in these three patients.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006982:Hypertonic Solutions; D002955:Leucovorin / Q000008:administration & dosage; D008206:Lymphatic Diseases / Q000188:drug therapy*; D008297:Male; D008353:Mannitol / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011344:Procarbazine / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D006982:Hypertonic Solutions; D011344:Procarbazine; D008353:Mannitol; D003907:Dexamethasone; D003520:Cyclophosphamide; D002955:Leucovorin; D008727:Methotrexate